Výsledky vyhledávání

Akademický článek

Molecular Landscape of ERBB2 Alterations in 14,956 Solid Tumors

Autor: Hao Wang, Ji Miao, Yazhou Wen, Xihua Xia, Yanan Chen, Mengli Huang, Shiqing Chen, Zhengyi Zhao, Yuzi Zhang, Chunzhu Chen, Xinhua Zhu

Publikováno v: Pathology and Oncology Research, Vol 28 (2022)

ERBB2 abnormalities frequently occur and serve as rationale therapeutic targets in cancer. In this study, clinical and next-generation sequencing data from 14,956 patients across more than 20 tumor types were collected. A total of 406 (2.7%) patients

Externí odkaz: https://doaj.org/article/763481088b5c4e1f87690abe0c283865

Zobrazit plný text záznamu

Anti-PD-1 plus anti-angiogenesis combined with chemotherapy in patients with HER2-negative advanced or metastatic gastric cancer: a multi-institutional retrospective study

Autor: Tongpeng Xu, Wenjie Wang, Ruikang Bao, Xihua Xia, Junling Zhang, Mengli Huang, Xiaofeng Chen, Rong Wang, Hao Zhang, Xisheng Liu, Qiong Li, Yongqian Shu

Publikováno v: Journal of Gastrointestinal Oncology. 14:175-186

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::001b41329b402b794a38c95cb77f844b
https://doi.org/10.21037/jgo-23-73

Zobrazit plný text záznamu

Clinical Impact of Switching to Ceritinib After Severe AEs Related to Crizotinib/Alectinib in a Novel PTH2R-ALK Fusion Lung Adenocarcinoma: A Case Report

Autor: Gang Shen, Yinping Du, Jifang Shen, Junling Zhang, Xihua Xia, Mengli Huang, Wenxiang Shen

Publikováno v: OncoTargets and therapy

Lung cancer is still the leading cause of morbidity and mortality by cancer among men, according to the latest epidemiological data in China. Anaplastic lymphoma kinase (ALK) rearrangements act as key oncogenic drivers of non-small cell lung cancer (

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d9322e4b40c2bd1be6cbb5a0d2f1af4
http://europepmc.org/articles/PMC8711735

Zobrazit plný text záznamu

Plný text ve formátu HTML

Molecular Landscape of

Autor: Hao, Wang, Ji, Miao, Yazhou, Wen, Xihua, Xia, Yanan, Chen, Mengli, Huang, Shiqing, Chen, Zhengyi, Zhao, Yuzi, Zhang, Chunzhu, Chen, Xinhua, Zhu

Publikováno v: Pathology oncology research : POR. 28

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::3d4db6a5f1222b6cb88466d8a82ca090
https://pubmed.ncbi.nlm.nih.gov/35911441

Zobrazit plný text záznamu

Abstract 5088: Identification of NOTCH mutation as novel predictor to efficacious immunotherapy in colorectal cancer

Autor: Xiaoyang Xia, DongShan You, Jing Cao, JingHui Huang, Junling Zhang, Mengli Huang, Yanan Chen, Xihua Xia, Yuezong Bai

Publikováno v: Cancer Research. 82:5088-5088

Background: NOTCH, as an oncogene, has been shown to be closely associated with radiation and chemotherapy, hormone therapy, and other molecular targeted therapies (such as anti-EGFR and anti-PI3K molecular targeted therapies) in a variety of tumors,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3cc1c5fc79930adb750ddc4e16246b64
https://doi.org/10.1158/1538-7445.am2022-5088

Zobrazit plný text záznamu

Abstract 5096: Characteristics of tumor immune microenvironment in patients carrying comutations of DNA damage response pathways in esophageal cancer

Autor: Hao Chen, Xihua Xia, Junling Zhang, Yanan Chen, Mengli Huang

Publikováno v: Cancer Research. 82:5096-5096

Background: Immunotherapy exhibits promising clinical efficacy in treating unresectable esophageal cancer, and several studies have demonstrated that both comutations in DNA damage response (DDR) pathways and tumor immune microenvironment(TIME) could

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a3cba0c58bf9a93ec59f1e6efca88d13
https://doi.org/10.1158/1538-7445.am2022-5096

Zobrazit plný text záznamu

Abstract 5090: Prognosis of renal cell carcinoma patients with VHL mutations to immune checkpoint inhibitors

Autor: Dong Shen, Yufeng Huang, Zhiwei Wu, Junling Zhang, Mengli Huang, Yanan Chen, Xihua Xia, Yuezong Bai

Publikováno v: Cancer Research. 82:5090-5090

Background: The von Hippel-Lindau (VHL) gene is a tumor suppressor gene. Although VHL gene alterations play a key role in the pathogenesis of renal cell carcinoma (RCC), and several therapies targeting this molecular pathway have been studied, such a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f2e1987bec53cdfc9b76eb3d75c4de85
https://doi.org/10.1158/1538-7445.am2022-5090

Zobrazit plný text záznamu

Abstract 5089: RNF43 mutation as a predictor of immunotherapeutic efficacy in colorectal cancer

Autor: Changjun Yu, Weibiao Kang, Yu Yuan, Junling Zhang, Mengli Huang, Yanan Chen, Xihua Xia, Yuezong Bai

Publikováno v: Cancer Research. 82:5089-5089

Background: RNF43, a single transmembrane circular E3 ubiquitin ligase, has been identified as a tumor suppressor for a variety of cancers, including ovarian cancer, gastric cancer, pancreatic cancer, endometrial cancer and colorectal cancer. It is e

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f6496f0b092f016da485e6a33a9ca547
https://doi.org/10.1158/1538-7445.am2022-5089

Zobrazit plný text záznamu

Abstract 5086: Effects of immune negative genes on immunotherapy combined anti-vascular for liver cancer

Autor: Xinhua Zhu, Yanan Chen, Junling Zhang, Mengli Huang, Xihua Xia

Publikováno v: Cancer Research. 82:5086-5086

Background: In recent years, the application of immune checkpoint inhibitors (ICIs) therapies targeting the programmed cell death-1 (PD-1)/programmed cell death ligand 1 (PD-L1) or cytotoxic T lymphocyte (CTLA-4) pathway represents a major breakthrou

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::48638472a70e034eac899df3e355f897
https://doi.org/10.1158/1538-7445.am2022-5086

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání